Major progress in kidney disease in 2015

doi:10.3969/j.issn.1004-583X.2016.02.008

Abstract

Abstract: In the past 2015, several aspects in kidney disease have increased dramatically, including the risk factors in kidney disease, diagnosis and treatment in primary and secondary kidney disease. The review describes the particularly progress in the biomarker of predictor and outcome of kidney disease, the diagnosis and treatment of primary kidney disease, secondary kidney disease and related complications.

Key words: nephrology, glomerulonephritis,membranous, hypertension, fibroblast growth factors

CLC Number:

R692

Xu Jinsheng, He Lei, Zhang Shenglei. Major progress in kidney disease in 2015[J]. Clinical Focus, 2016, 31(2): 168-174.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.02.008

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I2/168

References

[1] Yano Y, Fujimoto S, Kramer H, et al. Long-term blood pressure variability, new-onset diabetes mellitus, and new-onset chronic kidney disease in the Japanese general population[J]. Hypertension, 2015, 66(1): 30-36.
[2] Inker LA, Okparavero A, Tighiouart H, et al. Midlife blood pressure and late-life GFR and albuminuria: an elderly general population cohort[J]. Am J Kidney Dis, 2015, 66(2): 240-248.
[3] Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease[J]. N Engl J Med, 2015, 373(20):1916-1925.
[4] Rebholz CM, Grams ME, Coresh J, et al. Serum fibroblast growth factor-23 is associated with incident kidney disease[J]. J Am Soc Nephrol, 2015, 26(1): 192-200.
[5] Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study[J]. J Am Soc Nephrol, 2015, 26(9): 2248-2258.
[6] Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy[J]. N Engl J Med, 2015, 373(23): 2225-2236.
[7] Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy[J]. Am J Kidney Dis, 2015, 66(5): 783-791.
[8] Kao L, Lam V, Waldman M, et al. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 291-301.
[9] Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 302-313.
[10] Khan S, Bolton WK. Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2014, 9(6): 1001-1004.
[11] van den Brand JA, van Dijk PR, Hofstra JM, et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2014, 9(6): 1066-1073.
[12] Caro J, Gutierrez-Solis E, Rojas-Rivera J, et al. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus[J]. Nephrol Dial Transplant, 2015, 30(3): 467-474.
[13] Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(10): 2545-2558.
[14] Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care[J]. Lancet, 2015, 385(9981): 1983-1992.
[15] Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort[J]. Arthritis Rheumatol, 2015, 67(5): 1305-1313.
[16] Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)[J]. Nephrol Dial Transplant, 2015, 30 (Suppl 2): ii1-142.
[17] Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study[J]. Am J Kidney Dis, 2010, 55(3): 441-451.
[18] Rossignol P, Massy ZA, Azizi M, et al. The double challenge of resistant hypertension and chronic kidney disease[J]. Lancet, 2015, 386(10003): 1588-1598.
[19] Van Buren PN, Lewis JB, Dwyer JP, et al. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial[J]. Am J Kidney Dis, 2015, 66(3): 479-488.
[20] Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis[J]. J Am Soc Nephrol, 2015, 26(2): 493-503.
[21] Yamamoto T, Shoji S, Yamakawa T, et al. Predialysis and postdialysis pH and bicarbonate and risk of all-cause and cardiovascular mortality in long-term hemodialysis patients[J]. Am J Kidney Dis, 2015, 66(3): 469-478.
[22] Schutte E, Lambers Heerspink HJ, Lutgers HL, et al. Serum bicarbonate and kidney disease progression and cardiovascular outcome in patients with diabetic nephropathy: a post hoc analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin Ⅱ Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)[J]. Am J Kidney Dis, 2015, 66(3): 450-458.
[23] Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey[J]. Lancet, 2015, 386(10002): 1465-1471.
[24] Grams ME, Sang Y, Ballew SH, et al. A meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury[J]. Am J Kidney Dis, 2015, 66(4): 591-601.
[25] James MT, Grams ME, Woodward M, et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury[J]. Am J Kidney Dis, 2015, 66(4): 602-612.
[26] Barry R, James MT. Guidelines for classification of acute kidney diseases and disorders[J]. Nephron, 2015, 131(4): 221-226.